7- tert- butyldimethylsilyl- 10- hydroxycamptothecin

structure in first source

Also Known As:

1H-pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)- dione, 11-((1,1-dimethylethyl)dimethylsilyl)-4-ethyl-4,9- dihydroxy-, (4S)-; 7-t-butyldimethylsilyl-10-hydroxycamptothecin; AR 67 cpd; AR-67 cpd; DB 67; DB-67

Networked: 14 relevant articles (1 outcomes, 2 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Beckman, Eric J: 3 articles (09/2009 - 07/2008)
2.	Sivak, Wesley N: 3 articles (09/2009 - 07/2008)
3.	Zhang, Jianying: 3 articles (09/2009 - 07/2008)
4.	Leggas, Markos: 2 articles (07/2013 - 01/2010)
5.	Moscow, Jeffrey A: 2 articles (07/2013 - 01/2010)
6.	Tsakalozou, Eleftheria: 2 articles (07/2013 - 01/2010)
7.	Petoud, Stéphane: 2 articles (09/2008 - 07/2008)
8.	Pollack, Ian F: 2 articles (09/2008 - 07/2008)
9.	Zamboni, William C: 2 articles (09/2008 - 07/2008)
10.	Anderson, Bradley D: 2 articles (03/2008 - 08/2002)

Related Diseases

1.	Breast Neoplasms (Breast Cancer) 07/01/2013 - "The effect of breast cancer resistance protein, multidrug resistant protein 1, and organic anion-transporting polypeptide 1B3 on the antitumor efficacy of the lipophilic camptothecin 7-t-butyldimethylsilyl-10-hydroxycamptothecin (AR-67) in vitro."
2.	Neoplasms (Cancer) 01/15/2010 - "A phase I study of 7-t-butyldimethylsilyl-10-hydroxycamptothecin in adult patients with refractory or metastatic solid malignancies." 02/01/2010 - "In conclusion, DB-67 is more effective, compared to DB-91, against human tumor growth in in vitro, in vivo-like and in vivo systems. " 02/01/2010 - "While DB-91 showed limited activities, DB-67 exhibited activities against the growth of in vivo-like histocultured human tumors and s.c. " 02/01/2005 - "Together, our data show that DB-67 exhibits potent cytotoxicity and radiosensitization activity by targeting TOP1 in mammalian cells and has great potential for being developed to treat human cancers." 08/01/2002 - "A method for obtaining clear supersaturated aqueous solutions for parenteral administration of the poorly soluble experimental anti-cancer drug silatecan 7-t-butyldimethylsilyl-10-hydroxycamptothecin (DB-67) has been developed. "
3.	Glioma (Gliomas) 09/01/2008 - "DB-67 loaded LDI-glycerol polyurethane foams were found to inhibit cellular proliferation by at least 75% in all the malignant glioma cell lines tested (P<1.0x10(-8)). " 02/01/2005 - "As examined by clonogenic survival assay, DB-67 exhibited potent radiosensitization activity at a concentration 10-fold lower than camptothecin in the human glioma D54-MG and T-98G cells, which harbor wild-type and mutant p53, respectively. " 07/01/2008 - "LDI-glycerol polyurethane implants exhibit controlled release of DB-67 and anti-tumor activity in vitro against malignant gliomas."
4.	Disease Progression 07/01/2008 - "DB-67 has yet to be implemented in any clinical therapies due to the inability to delivered it in sufficient quantities to impact tumor growth and disease progression. "
5.	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 10/01/2004 - "The growth inhibition of the non-small-cell lung cancer cell lines A549 and H460 after exposure to DB-67 was evaluated with the MTS assay. " 10/01/2004 - "The effect of DB-67, a lipophilic camptothecin derivative, on topoisomerase I levels in non-small-cell lung cancer cells." 10/01/2004 - "To determine the in vitro drug sensitivity of two non-small-cell lung cancer cell lines after treatment with the novel lipophilic camptothecin derivative, 7- tert-butyldimethylsilyl-10-hydroxycamptothecin (DB-67), to determine if topoisomerase I protein levels decrease after treatment with DB-67, and to assess the duration and extent of topoisomerase I modulation after DB-67 exposure, in order to provide information about drug resistance that may be useful in determining an appropriate dosing schedule for DB-67. "

Related Drugs and Biologics

1.	Camptothecin
2.	Proteins (Proteins, Gene)
3.	Peptides (Polypeptides)
4.	Anions
5.	Indicators and Reagents (Reagents)
6.	lysine diisocyanate-glycerol poly(urea-urethane)
7.	Prodrugs
8.	Polyurethanes (Polyurethane)
9.	Phosphates (Orthophosphate)
10.	Lactones

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics
3.	Aftercare (After-Treatment)